Anavex Life Sciences Corp (AVXL)

[sokol]

Shorts are not as courageous as they sometime claim to be. They always have to worry about buying at higher prices because they reach a point where they cannot force the price any lower. When they have exhausted their ammunition by selling all they can afford and buying power becomes such that it resists the pressure of the shorts they find themselves in a weak position. The weakness in such a position is that all those who are short are potential bulls.

Granted, Anavex stock share price has performed poorly since July, and Anavex appears to me to be long due oversold. That is not to say that it has bottomed for sure. Extremes may be overdone.

However, Anavec is not about to go to O or belly up as some bears or shorts have casually suggested. The science behind the Anavex drug product pipeline is sound, and all of its of various drug candidates remain contenders for treatment of serious diseases some of which have potentially blockbuster market status (sales in the billion dollar range).

Shorting this stock is long on the tooth. There is plenty for shorts to fret about.

For a partial list of some things shorts/bears may worry about regarding Anavex, please see: http://seekingalpha.com/instablog/2635921-hessmessinc/4916745-anavex-life-sciences-potential-catalysts

1a. ALZ outside funding/partnership

1b. Breakthrough Therapy Designation for A 2-73

1c. PK/PD data for 12 and 26 weeks

1d. PR regarding the start of P3 ALZ and first patient enrolled

2a. IND Approval for Rett Syndrome

2b. Rett Syndrome outside funding/partnership

2c. Start of Rett Syndrome P2 with first patient enrolled (slightly bigger catalyst if a pivotal p2)

3. More longitudinal data from ALZ P2 extensions

4a. IND Approval for A 3-71

4b. Outside funding/partner for A 3-71 Phase 1

4c. Start of A 3-71 Phase 1

5a. IND Approval for Fragile X - Autism

5b. Outside funding/partner for P2 in Fragile X - Autism

6a. IND Approval for Infantile Spasms

6b. Outside funding/partner for P2 in Infantile Spasms

6c. Start of Infantile Spasms P2

7a. 2-73 Preclinical Parkinson's results - Page 85 c.ymcdn.com/sites/www.wpc2016.org/resour...

7b. IND Approval for Parkinson's

7c. Outside funding/partner for P2 in Parkinson's

7d. Start of Parkinson's P2 with first patient enrolled

8a. IND Approval for Epilepsy

8b. Outside funding/partner for P2 in Epilepsy

8c. Start of Parkinson's P2 with first patient enrolled

9a. IND approval for MS

9b. Outside funding/partner for P2 in MS

9c. Start of MS P2

10. 3-71 Preclinical Parksinson's results

11. 1-41 Preclinical Depression results

12. 1-41 Preclinical Stroke results

13. ODD for other indications

14. Dismissal of Lawsuit

15. Increased institutional investing

Moreover, in the coming week there may be near term developments to be reported. For example, there is the conference this next week sponsored by Mizuho Securities in Boston and the Parkinson's Conference in Oregon as well. All just around the corner.

For the Parkinson's Conference, see this: http://www.wpc2016.org/search/all.asp?bst=Anavex

And for the Mizuho conference see this: https://www.mizuhoamericas.com/who-we-are/events

Yet, there is more to come. We do not know what will come. It could be good news or bad news on an Anavex drug for a particular use, but Anavex has possibilities for a number of drug treatments or applications. Anavex is not a one trick pony, and none of its drugs have been disproven. Despite all the negativity in the last 8 or 9 weeks, it is far from over from over for Anavex as many have so quickly jumped to conclude, and it is now time for the shorts to worry. The shorts have had a good streak, but that could abruptly change for a lot of reasons -- only some of which are mentioned above.